|
KMID : 1200020190430050711
|
|
Diabetes & Metabolism Journal
2019 Volume.43 No. 5 p.711 ~ p.717
|
|
|
Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naive Patients with Type 2 Diabetes Mellitus
|
|
Kong Sung-Hye
Koo Bo-Kyung
Moon Min-Kyong
|
|
|
Abstract
|
|
|
Background: The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers.
Methods: This prospective, randomized, open-label, crossover study included drug-naive patients with type 2 diabetes mellitus, who were randomized to receive 8 weeks of initial treatment using metformin or dapagliflozin and crossed over for another 8 weeks of treatment after a 1-week washout period. Systemic endothelial function was evaluated via the reactive hyperemic index (RHI).
Results: The 22 participants included 10 males (45.5%) and had a median age of 58 years. The RHI values were not significantly changed during both 8-week treatment periods and there was no significant difference between the treatments. Relative to the metformin group, 8 weeks of dapagliflozin treatment produced significantly higher median N-acetyl-beta-D-glucosaminidase levels (10.0 ng/mL [interquartile range (IQR), 6.8 to 12.1 ng/mL] vs. 5.6 ng/mL [IQR, 3.8 to 8.0 ng/mL], P=0.013). Only the dapagliflozin group exhibited improved homeostatic model assessment of insulin resistance and body weight, while serum ketone and β-hydroxybutyrate levels increased.
Conclusion: Dapagliflozin treatment did not affect systemic endothelial function or renal injury markers except N-acetyl-beta-D-glucosaminidase.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, Disease management, Metformin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|